MX2020008699A - Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo. - Google Patents

Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo.

Info

Publication number
MX2020008699A
MX2020008699A MX2020008699A MX2020008699A MX2020008699A MX 2020008699 A MX2020008699 A MX 2020008699A MX 2020008699 A MX2020008699 A MX 2020008699A MX 2020008699 A MX2020008699 A MX 2020008699A MX 2020008699 A MX2020008699 A MX 2020008699A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
solution
amino
eye drop
Prior art date
Application number
MX2020008699A
Other languages
English (en)
Inventor
Dong-Yeop Shin
Hu-Seong Kim
Geun-Hyeog Lee
Kyung-Joon Kim
Yun-Seok Cho
O Mi-Jin
Mi-Jung Kim
Original Assignee
Hanlim Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanlim Pharmaceutical Co Ltd filed Critical Hanlim Pharmaceutical Co Ltd
Publication of MX2020008699A publication Critical patent/MX2020008699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Food Science & Technology (AREA)
  • Mechanical Engineering (AREA)

Abstract

La presente invención proporciona una formulación de gotas para los ojos en forma de una solución, que comprende (2R,3R,4S)-6-amino-4-[N-(4-clorofenil)-N-(1H-imidazol-2-ilmetil)a mino]- 3-hidroxi-2-metil-2-dimetoximetil-3,4-dihidro-2H-1-benzopir ano o una sal farmacéuticamente aceptable del mismo; propilenglicol como agente estabilizante; y un agente de control de pH en un medio acuoso, en donde la formulación de gotas para los ojos tiene un pH que varía de 4.0 a 5.0. La formulación de gotas para los ojos de la presente invención puede contener (2R,3R,4S)-6-amino-4-[N-(4-clorofenil)-N-(1Himidazol- 2-ilmetil)amino]-3-hidroxi-2-metil-2-dimetoximetil-3,4-dihidro-2H -1-benzopirano o una sal farmacéuticamente aceptable del mismo en una alta concentración; y tiene una excelente estabilidad. Además, el producto farmacéutico para prevenir o tratar la degeneración macular según la presente invención puede almacenarse durante períodos prolongados.
MX2020008699A 2018-02-28 2019-02-18 Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo. MX2020008699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180024470A KR102478553B1 (ko) 2018-02-28 2018-02-28 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제
PCT/KR2019/001894 WO2019168289A1 (ko) 2018-02-28 2019-02-18 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제

Publications (1)

Publication Number Publication Date
MX2020008699A true MX2020008699A (es) 2020-09-25

Family

ID=67805843

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008699A MX2020008699A (es) 2018-02-28 2019-02-18 Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo.

Country Status (15)

Country Link
US (1) US11771647B2 (es)
EP (1) EP3760188B1 (es)
JP (1) JP7160934B2 (es)
KR (1) KR102478553B1 (es)
CN (1) CN111801094B (es)
AU (1) AU2019226830B2 (es)
BR (1) BR112020017497A2 (es)
CA (1) CA3089091C (es)
ES (1) ES2953040T3 (es)
MX (1) MX2020008699A (es)
MY (1) MY198945A (es)
PH (1) PH12020551194A1 (es)
SG (1) SG11202007054VA (es)
WO (1) WO2019168289A1 (es)
ZA (1) ZA202005891B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250033790A (ko) * 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
KR20250038935A (ko) * 2023-09-13 2025-03-20 루다큐어 주식회사 8-옥소-2'-데옥시구아노신 또는 이의 약학적으로 허용가능한 염을 포함하는 수용액 형태의 점안제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69534258T2 (de) 1994-03-15 2006-05-04 Mitsubishi Pharma Corp. Verfahren zur Stabilisierung von Pranoprofen und stabile flüssige Zubereitung von Pranoprofen
JPH10236951A (ja) * 1996-12-27 1998-09-08 Teika Seiyaku Kk プラノプロフェン配合点眼剤
TW546151B (en) 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
KR100492252B1 (ko) 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
JP2011011984A (ja) 2009-06-30 2011-01-20 Lion Corp 仮性近視治療薬
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
EP2919802A4 (en) * 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
DK2950648T3 (da) 2013-02-01 2019-12-02 Ocuphire Pharma Inc Vandige oftalmiske opløsninger af phentolamin og medicinske anvendelser deraf

Also Published As

Publication number Publication date
AU2019226830B2 (en) 2024-01-11
MY198945A (en) 2023-10-03
NZ766624A (en) 2025-10-31
BR112020017497A2 (pt) 2020-12-22
KR102478553B1 (ko) 2022-12-16
RU2020125724A3 (es) 2022-04-29
SG11202007054VA (en) 2020-08-28
CN111801094A (zh) 2020-10-20
US11771647B2 (en) 2023-10-03
JP2021514995A (ja) 2021-06-17
KR20190103710A (ko) 2019-09-05
EP3760188A4 (en) 2021-10-20
US20200405634A1 (en) 2020-12-31
WO2019168289A1 (ko) 2019-09-06
ZA202005891B (en) 2022-03-30
AU2019226830A1 (en) 2020-08-13
EP3760188C0 (en) 2023-06-14
EP3760188A1 (en) 2021-01-06
CN111801094B (zh) 2022-11-18
CA3089091C (en) 2025-05-27
CA3089091A1 (en) 2019-02-18
PH12020551194A1 (en) 2021-08-16
JP7160934B2 (ja) 2022-10-25
ES2953040T3 (es) 2023-11-07
RU2020125724A (ru) 2022-03-28
EP3760188B1 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
CO2022018715A2 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
AR107014A1 (es) Formulación farmacéutica acuosa
MX2020010907A (es) Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central.
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
ES2545959T3 (es) Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer
EA201490803A1 (ru) Составы этанерцепта, стабилизированные ксилитом
CL2015003442A1 (es) Derivados heterociclicos
DE602006006308D1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MX2017008189A (es) Composicion farmceutica que comprende plasminogeno y usos de este.
AR112103A1 (es) Compuestos para el tratamiento de tnbc
AR105199A1 (es) Soluciones oftálmicas acuosas
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
MX2019003698A (es) Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada.
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
CL2017000120A1 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
MX2021012708A (es) Formulaciones novedosas que comprenden melflufen.
PE20230112A1 (es) Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria
CO2023002650A2 (es) Formas farmacéuticas sólidas de palbociclib
ES2531241T3 (es) Composición farmacéutica líquida estable a base de trazodona
BR112019000897A2 (pt) sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão.
PH12020551194A1 (en) Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
MX2016006651A (es) Soluciones para incrementar la estabilidad y la vida util de una solucion de conservacion de organos y tejidos.
MX2021013405A (es) Estabilizacion de concentrados en suspension mediante ricinoleina etoxilada.